Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience

Sbrana, Andrea; Biasco, Elisa; Paolieri, Federico; Palesandro, Erica; Caserta, Claudia; Iacovelli, Roberto; Detti, Beatrice; Santini, Daniele; Mosca, Alessandra; Morelli, Franco; Fornarini, Giuseppe; Giorgi, Ugo De; Masini, Cristina; Galli, Luca

doi:10.21873/anticanres.12807

Cited by 5 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“….Analogous results have been presented for Pazopanib [31,32] and Sorafenib [33], but in no case they could provide clinical guidance for the optimal use of these agents in latter lines of therapy.…”

Section: Discussionmentioning

confidence: 76%

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Tsironis

Liontos

Kyriazoglou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically. Methods: Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included. Results: Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events. Conclusions: Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.

show abstract

Section: Discussionmentioning

confidence: 76%

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Tsironis

Liontos

Kyriazoglou

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Analogous results have been presented for Pazopanib [27,28] and Sorafenib [29], but in no case they could provide clinical guidance for the optimal use of these agents in latter lines of therapy. Probably molecular biomarkers are needed to guide sequence of treatments amidst the complex therapeutic algorithm of mRCC as could be the case of PBRM1 for immunotherapy post TKIs.…”

Section: Safetymentioning

confidence: 68%

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Tsironis

Liontos

Kyriazoglou

et al. 2020

Preprint

View full text Add to dashboard Cite

Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically. Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.

show abstract

“…Long term response to sunitinib has been studied retrospectively from several authors concluding that the absence of adverse disease characteristics (poor PS, poor MSKCC risk, absence of bone or liver metastases) may predict long responders [27][28][29]. Analogous results have been presented for Pazopanib [30,31] and Sorafenib [32], but in no case they could provide clinical guidance for the optimal use of these agents in latter lines of therapy.…”

Section: Discussionmentioning

confidence: 99%

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

et al. 2020

View full text Add to dashboard Cite

Background: Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically. Methods: Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent-Axitinib, a tyrosine kinase inhibitor-as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included. Results: Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events. Conclusions: Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.

show abstract

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience

Abstract: Pazopanib therapy may be suitable for all patients with mRCC, and especially in those with PS 0.

Cited by 5 publications

References 2 publications

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Axitinib as a third or further line of treatment in renal cancer. A single institution experience

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

Contact Info

Product

Resources

About